<DOC>
	<DOCNO>NCT00853047</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability LX1606 versus placebo control subject symptomatic carcinoid syndrome manage stable-dose long-acting octreotide therapy . Following determination maximally tolerate effective dose , cohort expansion occur confirm effect symptom safety profile .</brief_summary>
	<brief_title>Study LX1606 Subjects With Symptomatic Carcinoid Syndrome Not Managed Stable-Dose Octreotide Therapy</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<criteria>Males female , age 18 old Biopsyproven metastatic carcinoid tumor GI tract disease extent confirm CT , MRI , radionuclide imaging Symptoms manage stabledose longacting octreotide therapy ( ≥4 bowel movement per day ) Ability provide write informed consent ≥12 high volume , watery bowel movement per day Sponsorunacceptable clinical laboratory value hematology liver function test screen Karnofsky status ≤70 % unable care self Surgery within 60 day prior screen A history short bowel syndrome Life expectancy &lt; 12 month History substance alcohol abuse within 2 year prior screen Previous exposure tryptophan hydroxylase ( TPH ) inhibitor Administration investigational drug within 30 day screen therapeutic protein antibody within 90 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>